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Abstract
 
Transcription of the human immunodeficiency virus (HIV)-1 is controlled by the cooperation
of virally encoded and host regulatory proteins. The Tat protein is essential for viral replication,
however, expression of Tat after virus entry requires HIV-1 promoter activation. A sequence
in the 5
 
 
 
 HIV-1 LTR, containing a binding site for transcription factors of the interferon regu-
latory factors (IRF) family has been suggested to be critical for HIV-1 transcription and replica-
tion. Here we show that IRF-1 activates HIV-1 LTR transcription in a dose-dependent fash-
ion and in the absence of Tat. This has biological significance since IRF-1 is produced early
upon virus entry, both in cell lines and in primary CD4
 
 
 
 T cells, and before expression of Tat.
IRF-1 also cooperates with Tat in amplifying virus gene transcription and replication. This
cooperation depends upon a physical interaction that is blocked by overexpression of IRF-8,
the natural repressor of IRF-1, and, in turn is released by overexpression of IRF-1. These data
suggest a key role of IRF-1 in the early phase of viral replication and/or during viral reactiva-
tion from latency, when viral transactivators are absent or present at very low levels, and suggest
that the interplay between IRF-1 and IRF-8 may play a key role in virus latency.
Key words: virus replication • Tat • transcription factors • gene expression • T lymphocytes
 
Introduction
 
Replication of the HIV-1 provirus is mainly controlled at
 
the transcriptional level and depends on a complex inter-
play between the viral transregulatory protein Tat and
cellular transcription factors with the LTR and the in-
tragenic enhancer in the pol gene (1–4). Several major
DNase-hypersensitive sites associated with the LTR pro-
moter and target sequences for regulatory proteins have
been identified (5, 6).
In the HIV-1 LTR transcriptional regulatory elements
are present both upstream and downstream the transcrip-
tional start site. DNaseI sensitivity studies identified just
downstream the 5
 
 
 
 LTR (5) a region spanning nt 
 
 
 
200 to
 
 
 
217 that is homologous to the IFN-stimulated response
 
element (ISRE)
 
*
 
 present in the promoter of IFN-stimulated
genes (ISGs; reference 7). This sequence is a binding site for
members of the IFN regulatory factor (IRF) protein family
(8) and plays a critical role in HIV-1 transcription and repli-
cation leading to the definition of a new positive transcrip-
tional regulatory element in the HIV-1 provirus (8, 9).
IRFs play a key role in gene regulation by IFNs and viral
infections as well as in several immunological and growth-
related cellular functions (10, 11). Nine members of this
family have been identified to date based on a homologous
DNA-binding domain located at the NH
 
2
 
 terminus re-
sponsible for binding to the ISRE. The less conserved
COOH-terminal region acts as a regulatory domain and
classifies IRFs into three groups: those that activate
(IRF-1, IRF-3, IRF-7, and IRF-9/ISGF-3
 
 
 
), those that
repress (IRF-2, IRF-8/ICSBP), and those (IRF-2, IRF-4/
LSIRF/Pip) that are able both to activate or to repress gene
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transcription depending on the target gene. IRFs interact
with each other and with other families of transcription
factors modifying both ISRE-binding activities and the for-
mation of initiation transcription complexes. In addition
IRF-1, IRF-2, and IRF-3 can interact with components of
the basal transcriptional machinery as well as with the his-
tone-acetyltransferases (12–14).
The HIV-1 transactivator protein Tat is a 
 
 
 
14/15-kD
protein produced early after infection and before virus inte-
gration (15), which is absolutely required for productive vi-
rus replication (16, 17). Tat has been shown to modulate vi-
ral gene expression by increasing the rate of transcription
initiation, elongation, and translation of TAR-containing
mRNAs (3, 18–20). Several reports also suggest that Tat
can dissociate from TAR to bind either elongating RNA
polymerase II (21) or DNA-tethered promoter factors (22,
23). Tat has the capability of augmenting transcription of
viral as well as cellular genes by both TAR-dependent and
TAR-independent mechanisms (24–28) also by acting as a
DNA sequence–specific transcription factor in the absence
of TAR and other HIV-1 LTR sequences (29).
Both specific and basal cellular transcription factors are
key in Tat-mediated transactivation of virus gene expres-
sion, including Sp1 (22), TBP (30) and TAFII 55 (31),
TAP, (32, 33), the kinases TAKs (34), and NF-
 
 
 
B (25). In
addition, Tat relieves the transcriptionally inactive chroma-
tin-associated proviral LTR through the recruitment of
Tat-associated histone acetyltransferases TAHs (35–37).
The mechanism of action of Tat is complex and not yet
completely defined. Similarly, it has not yet been completely
elucidated how the viral genome initiates early transcrip-
tion immediately after viral entry when Tat is still absent or
at a threshold concentration, or how the integrated HIV-1
genome reactivates from latency, before viral transactivators
are produced.
Here we show that upon entry, HIV-1 is able to induce
IRF-1 expression before the expression of Tat. IRF-1 is ca-
pable per sé of driving LTR-mediated transactivation in a
dose-dependent fashion. In addition, IRF-1 increases Tat-
mediated transactivation of the HIV-1 LTR via a physical
interaction of its COOH-terminal domain with Tat. This
positive cooperation is blocked by IRF-8, a physiological
repressor of IRF-1 activity, which inhibits Tat-mediated
LTR transcription and viral replication in vivo. These results
identify IRF-1 as essential for efficient HIV-1 gene expres-
sion and viral replication and indicate that the recruitment of
IRF-1 to the HIV-1 promoter can be a key step in the early
phases of infection or during viral reactivation from latency,
in response to both viral infection and cell activation signals.
 
Materials and Methods
 
Cell Cultures and Treatments.
 
Jurkat and 293 HEK cells were
grown in RPMI 1640 medium (Bio-Whittaker) or MEM, re-
spectively, containing 10% FCS and antibiotics (growth me-
dium). rIFN-
 
 
 
 (Pepro Tech EC LTD) was used at 10 ng/ml.
Human PBLs from healthy donors were isolated by Ficoll-
Hypaque gradient and the CD4
 
 
 
 T cell population purified by
 
negative selection using magnetic beads (Miltenyi Biotech) coated
with mAbs directed against CD8, CD19, CD16, CD56, and
CD11b by manufacturers’ instructions. The recovered cells were
 
 
 
96% CD3
 
 
 
 as determined by FACS
 
®
 
 analysis. Purified cells
were cultured in growth medium and activated with anti-CD3
mAb (Clone FM-18; Biosource International).
 
Plasmids.
 
The HIV-LTR-CAT construct contains the chlor-
amphenicol acetyltransferase (CAT) gene linked to the HIV-1
LTR BH10 clone (
 
 
 
454 to 
 
 
 
286) (9). 
 
 
 
1
 
 LTR corresponds to
the BH10-LD1 which is deleted in the ISRE sequence (9). 
 
 
 
2
 
LTR and 
 
 
 
3
 
 LTR were obtained from the HIV-LTR-CAT and
 
 
 
1
 
 LTR, respectively, by site-directed mutagenesis of the NF-
 
 
 
B
site using the QuickChange site-directed mutagenesis kit (Strat-
agene). The sequence of the primer used to induce the specific
mutation was: 5
 
 
 
 CGAGCTTGCTACAACTCACCGCTGCT-
CACCCAGGGAGG 3
 
 
 
.
CMV-Tat, CMV-IRF-1, CMV-IRF-2, CMV-IRF-3.5D, and
CMV-IRF-7
 
*
 
 (S477D/S479D) expression vectors have been
described previously (38–41); the IRF-8 expression vector (pTar-
get-ICSBP) was a gift of B. Levi, Technion-Israel Institute of
Technology, Haifa, Israel; IRF-4 expression vector was a gift of
I. Julkunen, National Public Health Institute, Helsinki, Finland.
The pIRF-1/Hygro construct was generated by cloning the frag-
ment excised from pUC-IRF-1 (a gift of T. Taniguchi, Univer-
sity of Tokyo, Tokyo, Japan) by XbaI and HindIII digestion in
the pcDNA3.1/Hygro plasmid (Invitrogen Corp.).
All plasmids used in the transfection experiments were purified
by cesium chloride.
 
Stable and Transient Transfection Experiments.
 
Stable transfec-
tants of Jurkat cells were obtained by electroporation with a Bio-
Rad gene pulser transfection apparatus using a field strength 0.875
KV/cm, a capacitance of 25 
 
 
 
F and a time constant 
 
 
 
10 
 
 
 
s.
Cells were selected for 2 wk with 0.5 mg/ml Geneticin G-418
sulfate (GIBCO BRL).
Jurkat cells expressing both IRF-1 and IRF-8 were obtained by
transfecting the IRF-8–expressing cells with the pIRF-1/Hygro.
After 10 d of selection in growth medium containing 350 
 
 
 
g/ml
of Hygromycin (Sigma-Aldrich), cells were amplified on medium
containing both hygromycin and geneticin G-418 sulfate.
Bulk populations were frozen and aliquots periodically thawed
(every 4–6 wk) to maintain the identity of the polyclonal cell
population. Transient transfections experiments were performed
using the FuGENE 6 Transfection Reagent (Roche Laborato-
ries) according to the manufacturer’s protocol. Amounts of trans-
fected DNA were normalized by using RcCMV vector. A
cotransfected RcCMV 
 
 
 
-gal plasmid was used to normalize for
transfection efficiency.
 
Enzymatic Assays.
 
CAT assay was performed as described
previously (42). 
 
 
 
-gal assay was performed using the 
 
 
 
-galactosi-
dase Enzyme Assay system (Promega).
 
EMSA.
 
EMSA with nuclear cell lysates (6 
 
 
 
g; reference 43)
was performed as described previously (42). For supershift analy-
sis, nuclear extracts were incubated with polyclonal anti–IRF-1
and anti–IRF-2 (a gift of Dr. J. Hiscott) antibodies in binding
buffer containing the oligonucleotide probe (C
 
13
 
 [AACTGA]
 
4
 
)
for 30 min on ice.
 
DNA Affinity Purification Assay.
 
A biotinylated oligonucle-
otide corresponding to the HIV-ISRE (AGGGACTTGA-
AAGCGAAAGGGAAACCAGAG) or a mutant oligonucleotide
(AGGGACTTGACCGCGGGGCCACCAGAG) were synthe-
sized (Invitrogen) and then annealed with the corresponding anti-
sense oligonucleotides in 1
 
  
 
STE buffer, containing 10 mM
Tris-HCl, pH 8.0, 50 mM NaCl and 2 mM EDTA. 25 pico- 
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moles of biotinylated DNA were mixed with 100–200 
 
 
 
g of
nuclear extract in 200 
 
 
 
l of binding buffer containing 20 mM
Tris-HCl, pH 7.5, 75 mM KCl, 1 mM DTT, and 5 
 
 
 
g/ml BSA
in the presence of 10% glycerol and 20 
 
 
 
g of poly(dI-dC) and in-
cubated for 25 min at room temperature. The complex was pull-
down with magnetic beads (Streptavidin MagneSphere; Promega)
for 30 min at 4
 
 
 
C and for 10 min at room temperature by mixing
with rotation. The collected beads were washed and bound mate-
rial eluted by boiling in sample buffer. Eluted proteins were sepa-
rated onto 10% SDS-PAGE followed by immunoblotting with
antibody against IRF-1.
 
Western Blot Analysis.
 
Western blot (WB) was performed as
described previously (42). Polyclonal antibodies against IRF-1
was a gift of R. Pine, Public Health Institute, New York, NY.
 
Immunoprecipitation and Immunoblot Analysis of the Interactions be-
tween IRF-1 and Tat.
 
293 HEK cells were contransfected with
expression plasmids encoding IRF-1 or Tat. Whole cell extracts
(200–300 
 
 
 
g) were precleared with rabbit IgG nonimmune anti-
sera cross-linked to ultralink immobilized protein A-G (Pierce
Chemical Co.), and incubated with anti–IRF-1 antibodies (C20;
Santa Cruz Biotechnology, Inc.) cross-linked to ultralink immo-
bilized protein A-G sepharose for 1 h at 4
 
 
 
C. Immunoprecipitates
were washed five times with lysis buffer and eluted by boiling the
beads for 3 min in 1
 
 
 
 SDS sample buffer. Eluted proteins were
separated by SDS-PAGE and subjected to WB.
 
RNA Extraction and Protection Analysis.
 
Total RNA was iso-
lated by the guanidinium-cesium chloride method (44). RNase
protection was performed with 5 
 
 
 
g of total RNA as described
previously (42).
To generate the 
 
32
 
[P]-labeled 280-bp long antisense IRF-1
RNA probe, the pBS-IRF-1 plasmid (45) was linearized with
EcoRI and transcribed by T7 polymerase. To generate the 
 
32
 
[P]-
labeled 280-bp long antisense IRF-8 RNA probe, the plasmid
(pBS-BP) was linearized with PvuII and transcribed by T7 poly-
merase. The plasmid pBS-BP was generated by cloning a 1,400-
bp long fragment obtained by EcoRI digestion from the plasmid
pTarget-ICSBP containing the entire IRF-8 cDNA. A 18S
RNA probe was used as a control for equal RNA loading.
 
Virus Stock Preparation and Infection.
 
Replication-competent T
cell-tropic virus was made by transfecting Jurkat cells with the
pHXB2R molecular clone, as described previously (46). Viral in-
fection assays were performed by inoculating 10
 
6
 
 cells with 1,000
or 5,000 cpm of RT activity corresponding to 0.001 or 0.005 50%
TCDI/cell of HIV-1/HXB2. After 2 h, virus was washed out and
cells were cultured for 96 h. Virus production was then monitored
at 24, 48, 72, and 96 h after infection by measuring the levels of
p24 in the culture supernatants with a commercial assay kit (p24/27
core antigen assay; Innogenetics) as specified by the manufacturer.
 
RT-PCR Analysis.
 
To isolate total cellular RNA, 10 
 
 
 
 10
 
6
 
cells were processed using the RNA easy-total RNA extraction
kit from QIAGEN. Total RNA was treated with RNase-free
DNaseI (Boeringher Mannheim). RT was performed in 50 
 
 
 
l re-
action volume containing 1 
 
 
 
g of total RNA according to the
manufacturer’s instruction (RNA PCR kit; Perkin Elmer). To
control for the presence of genomic DNA, control cDNA reac-
tion mixture from which RT was omitted were prepared in par-
allel. These were uniformly negative (data not shown).
The specific primers named M667, M668, LA45, LA41,
M669, and LA23 used to amplify HIV transcripts and PCR con-
ditions were described previously (47). To detect the PCR prod-
uct of the primer pair M667/M668 and M669/LA23, 
 
32
 
[P]-
labeled primer M669 and M668, respectively, were used for
hybridization. Detection of the PCR product using specific
primers LA41-LA45 were revealed by hybridization with 
 
32
 
[P]-
labeled oligonucleotide designed to span in between the first and
the second Tat exons: TCAAAGCAACCCACCTCCCAA.
To evaluate the expression of the IRF-1 gene, an aliquot of re-
verse-transcribed-RNA was amplified within the linear range by
25 PCR cycles: denaturation at 94
 
 
 
C for 30 s, annealing at 56
 
 
 
C
for 30 s, and extension at 72
 
 
 
C for 30 s. The RT-PCR was nor-
malized for 26S. Each sample was electrophoresed onto 1% aga-
rose, transferred to nylon membrane and hybridized with a specific
probe. The following primers and probe for IRF-1 were used:
primer 5
 
 
 
: GTCCAGCCGAGATGCTAAGAGC; primer 3
 
 
 
:
GGCTGCCACTCCGACTGCTCC; and probe: GGCCAA-
GAGGAAGTCATGTGGG.
The primers and probe for 26S amplification were: primer 5
 
 
 
:
GCCTCCAAGATGACAAAG; primer 3
 
 
 
: CCAGAGAAT-
AGCCTGTCT; and probe: GAGCGTCTTCGATGCCTAT-
GTGCTTCCCAA.
 
Construction of the Two-Hybrid Clones.
 
The IRF-1 open read-
ing frame (ORF) was PCR-amplified using primers that intro-
duced an EcoRI and an XhoI site at the 5
 
 
 
 and 3
 
 
 
 ends, respec-
tively, and inserted in the pEG202LexA yeast expression vector
in frame with LexA (48). The clones were then transferred in the
YEplac181GLexA202 vector and used for the yeast two-hybrid
interaction assay. The truncated forms IRF-1 (1–291) and IRF-1
(1–234) were constructed by removal of the 3
 
 
 
 coding sequences
with AccI and Bsu36I, respectively, followed by the Klenow
treatment. For the construction of the VP16-Tat clone, the Tat
86 amino acids open reading frame was PCR-amplified from the
CMV-Tat plasmid using primers that introduced an EcoRI and
an XhoI site at the 5
 
 
 
 and 3
 
 
 
 ends, respectively, and cloned in the
yeast expression vector pRS314VP16 (49).
The ORFs obtained as described above were cloned into the
bacterial expression vector pGEX-4T-1 (Amersham Pharmacia
Biotech) at EcoRI and XhoI sites. All the constructs were rese-
quenced after identification.
 
Two-Hybrid Yeast Assay.
 
The two-hybrid yeast assay was per-
formed as described previously (48). Yeast cells harboring a
LexA-responsive LacZ reporter plasmid were cotransformed with
a LexA/IRF-1 plasmid, and a VP16/Tat plasmid. Transformants
were selected at 30
 
 
 
C on YMM plates. From each transformation
three colonies were grown in selective minimal liquid media be-
fore galactose-induced expression of the fusion proteins. After in-
cubation of 24 h at 30
 
 
 
C with 2% galactose, yeast cells were used
in the permeabilized cell assay (50) to determine the 
 
 
 
-galactosi-
dase activity resulting from the LacZ reporter gene expression.
 
In Vitro GST Pull-Down Experiments.
 
GST and GST fusion
proteins were expressed in 
 
Escherichia coli
 
 BL21:DE3(pLysS) (48).
For the in vitro binding experiments, 
 
 
 
2 
 
 
 
g of GST and GST–
Tat or GST–IRF-1 were mixed with the 
 
35
 
[S]-labeled rIRFs
and/or Tat proteins synthesized in vitro using the coupled TNT
transcription/translation system (Promega TNT system) in 500 
 
 
 
l
of PBS containing 0.1% BSA, 0.5% NP-40, 10% glycerol, and
protease inhibitors. Binding reaction was allowed at 4
 
 
 
C for 90
min. Beads were washed, resuspended in sample buffer, and sub-
jected to SDS-PAGE. Gels were analyzed by electronic autora-
diography in an Instant Imager (Camberra Packard).
 
Results
 
IRF-1 Activates Transcription from the HIV-1 LTR and In-
creases Tat-mediated Transactivation of LTR-directed Gene Ex-
pression.
 
The effect of IRFs on HIV-1 transactivation 
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was evaluated in Jurkat cells transiently cotransfected with
vectors expressing IRF-1, IRF-4, or the constitutively
activated forms of IRF-3 (IRF-3 5D) and IRF-7 and
a HIV-1 LTR-CAT reporter construct (nt 
 
 
 
456 to nt
 
 
 
286). As shown in Fig. 1 A, the basal activity of the
HIV-LTR was increased only by the presence of IRF-1,
whereas no or little increase was detected in the presence
of the other IRFs.
Therefore, the effect of IRF-1 was further analyzed.
IRF-1 increased HIV-1 LTR-directed gene expression in a
dose-dependent fashion (Fig. 1 B), whereas no activation
was detected by deleting the entire COOH-terminal activa-
tion domain of IRF-1 (
 
 
 
 IRF-1). This indicated that upon
HIV-1 infection IRF-1 can activate transcription of Tat.
To investigate whether the effect of IRF-1 was mediated
by the ISRE, an ISRE-deleted (
 
 
 
1
 
 LTR) or a NF-
 
 
 
B mu-
tated ( 2 LTR) construct were used. As shown in Fig. 1 C,
IRF-1 was still capable of transactivating the HIV-1 LTR.
On the contrary, transactivation was greatly reduced when
a mutant bearing deletions in both the ISRE and the NF-
 b sites ( 3 LTR) was used. These results indicate that the
ISRE is not the major site mediating the IRF-1 effect.
To determine the effect of the simultaneous presence of
IRF-1 and Tat on HIV-1 LTR transactivation, Jurkat cells
were cotransfected with the HIV-LTR construct and with
both Tat and IRF-1 expression vectors (Fig. 1 D). The
presence of IRF-1 had additive effects on the HIV-1 LTR-
CAT activity induced by suboptimal expression of Tat,
whereas the cooperative effect was not evident when Tat
was overexpressed (data not shown). This suggests that
Tat/IRF-1 effect may be key in the very early phase of in-
fection, when Tat is absent or still at low levels.
HIV-1 Induces IRF-1 Early Upon Infection and Prior to Ex-
pression of Tat in both T Cell Lines and Primary CD4  T
Cells. To determine whether IRF-1 is induced by HIV-1
and whether this occurs before Tat expression, Jurkat cells
were infected with the HIV-1 IIIB strain at a low multi-
plicity of infection and IRF-1 RNA expression analyzed by
RNase protection and tat/rev RNA by semiquantitative
RT-PCR analysis at different time points after infection.
As shown in Fig. 2 A, discrete basal levels of IRF-1 mRNA
were detected in Jurkat cells, which increased by 3- and
2.5-fold, respectively, after 5 and 7 h after infection (Fig. 2
A and B). This increase was already detectable at 3 h after
infection (data not shown) and returned to basal levels
within 24 h. A parallel increase in the protein levels was
also detected (Fig. 4).
Notably, at the moment of the highest IRF-1 expression
(5 h after infection), no doubly/spliced HIV tat/rev RNA
transcripts were detected, whereas at 24 h after infection, as
expected, the tat/rev mRNA was clearly detectable. Thus,
HIV-1 induces IRF-1 expression early upon infection and
before production of Tat.
To assess the biological relevance of these findings, ex-
periments were repeated with primary purified CD4  T
lymphocytes stimulated with anti-CD3 mAb and infected
with the same virus. IRF-1 and tat/rev RNA expression
were then analyzed by RT-PCR at different time points
after infection.
As shown in Fig. 3, very low expression of IRF-1 was
present in freshly isolated cells, which increased upon stim-
ulation with anti-CD3 antibody (approximately twofold),
consistently with previous data (51). However, starting
from 5 h after infection IRF-1 mRNA increased by four-
Figure 1. Effect of IRFs on HIV-1 LTR trans-
activation. (A) Jurkat cells were transiently
cotransfected with the HIV-1 LTR-CAT (1  g)
and vectors (2  g) expressing the indicated IRFs.
IRF-3 5D and IRF-7* codify for the constitu-
tively activated forms of IRF-3 and -7, respec-
tively (references 40 and 41). After 24 h, CAT
activity was evaluated as indicated in the Materi-
als and Methods. (B) Dose–response effect of the
wild-type IRF-1 or its mutant deleted in the ac-
tivation domain (  IRF-1) on HIV-1 LTR-
directed gene expression. Cells were transfected
as in A except that 0.8  g of HIV-1 LTR-CAT
and increasing amounts of the vectors expressing
IRF-1 or   IRF-1 (0.8, 1.6, 3.2  g) were used.
(C) Effect of IRF-1 on mutated HIV-LTR con-
structs. Cells were transiently transfected with
wild-type HIV-LTR or  1 LTR in which the
ISRE region is deleted (reference 9),  2 LTR in
which the NF- B sites are mutated or  3 LTR in
which both sites are deleted/mutated. IRF-1–
expressing vector was cotransfected as indicated.
Results are shown as percentages of the CAT ac-
tivity of the wild-type HIV-LTR in IRF-1–
transfected cells. (D) IRF-1 cooperates with Tat
to enhance HIV-1 LTR-CAT activity. Cells
were transiently cotransfected with the HIV-1
LTR-CAT (1  g), Tat (5 ng), or IRF-1 (1  g)
expressing vectors, either alone or in combination, as indicated. CAT activity was determined after 24 h. The results quantified by an Instant Im-
ager are reported as mean levels   SE from three separate experiments.1363 Sgarbanti et al.
fold and its expression peaked at 24 h after infection (sev-
enfold increase over basal levels). A progressive decrease
was then observed as found with Jurkat cells. However,
when the IRF-1 stimulation was maximal, no doubly
spliced tat/rev RNA transcripts were detected (Fig. 3 C). A
similar kinetic of IRF-1 induction was observed with three
different healthy donors.
IRF-1–specific Binding Activity in Infected Cells. To test
whether stimulation of IRF-1 upon HIV-1 infection was
associated with the presence of a IRF-1–specific binding
activity, EMSA was performed by incubating nuclear cell
extracts from infected cells with an oligonucleotide repre-
senting the canonical IRF binding site (C13). As shown in
Fig. 4 A, discrete complexes were detected both in unin-
fected and infected cells at all time points after infection,
which contained both IRF-1 and IRF-2 or multimers of
IRF-2 (52) as anti–IRF-1 and anti–IRF-2 antibodies su-
pershifted the higher-mobility and lower-mobility shifted
bands, respectively.
However, early after infection, a specific increase of
IRF-1-containing complexes was observed (compare lane
6 versus lane 3), consistent with RNA expression data (Fig.
2). From 7 h after infection onward, IRF-1–specific com-
plexes diminished reaching values comparable or below to
those observed in uninfected cells. A control purified rab-
bit IgG and specific anti–IRF-3, -4, -7 antibodies did not
affect the binding of any complex (data not shown). To
determine the IRF-1–specific binding activity to the HIV-1
LTR, DNA affinity purification assays were performed
with both Jurkat and primary CD4  T cell extracts at 7
and 24 h after infection in the presence of a biotinylated
HIV-ISRE probe. The isolated complexes were then ex-
amined by immunoblotting against IRF-1. As shown in
Figure 2. IRF-1 mRNA is
induced early upon HIV-1 in-
fection and before expression of
Tat. (A) Jurkat cells were in-
fected with the HIV-1 strain
IIIB (5,000 cpm/ml) and, at the
indicated time points, total RNA
was extracted and analyzed by
RNase protection with a IRF-1–
specific antisense riboprobe. 18S
rRNA was used as a control of
RNA loading. (B) mRNA rela-
tive fold-increase after normal-
ization to the 18S RNA, quanti-
fied by Instant Imager. Mean
values from three separate experiments are shown. (C) Total RNA ex-
tracted at 5 and 24 h after infection shown in A was analyzed by RT-
PCR for the doubly-spliced (tat/rev) transcript as described in Materials
and Methods.
Figure 3. HIV-1 infection in-
duces IRF-1 mRNA expression
in primary CD4  T lympho-
cytes. (A) Purified CD4  T
cells were infected with the
HIV-1 IIIB strain (5,000 cpm/
ml) and IRF-1 mRNA evalu-
ated by semiquantitative RT-
PCR analysis at the indicated
time points after infection. A
representative experiment out of
three performed is shown. The
increase in IRF-1 mRNA accu-
mulation begun to be evident
between 5 and 12 h after infection and peaked between 24 and 48 h after
infection depending on the donor. 26S RNA was used for normalization
as described in Materials and Methods. (B) mRNA relative fold-increase
after normalization to the 26S RNA quantified by Instant Imager. (C)
Total RNA extracted at the indicated time points as in A was analyzed
by RT-PCR for the doubly-spliced (tat/rev) transcript as described in
Materials and Methods.1364 IRFs and HIV-1 Replication
Fig. 4 B, an increasing IRF-1 binding was evident in infected
cells at 7 h after infection, which after 24 h returned to basal
levels in Jurkat cells but was still present in CD4  T cells,
according to the RNA expression data (Figs. 2 and 3). This
corresponded to the presence of IRF-1 protein (INPUT,
Fig. 4 B, right panels) in the same cell extracts. In addition,
IRF-1–binding was highly specific since a mutated oligo-
nucleotide (HIV-1-ISRE mut) or an unrelated one (data not
shown) did not retain any protein from the same cell extracts.
Taken together, these results demonstrate that IRF-1
and IRF-2 bind to the ISRE-like motif of the HIV-1
LTR. However, early after virus infection, IRF-1 expres-
sion increases and this correlates with increasing protein
levels and binding to specific LTR-target sequences.
Specific and High-Affinity Binding of IRF-1 and Tat
GST Pull-Down Experiments. To determine whether
the cooperative effect of Tat and IRF-1 on HIV-1 LTR
transactivation (Fig. 1 D) is mediated by physical interac-
tions between the two proteins, GST pull-down assays
were performed. IRF-1 was translated in vitro and tested
for binding to a GST–Tat fusion protein. As shown in Fig.
5, the GST–Tat protein bound strongly to IRF-1, i.e., up
to 30% of the IRF-1 input was bound to the immobilized
Tat protein, whereas no binding was detected to control
beads containing GST alone. In contrast, IRF-2, IRF-3,
IRF-4, IRF-7, and IRF-8 did not bind to Tat. IRF-1 and
Tat binding was also detected when a GST–IRF-1 fusion
protein was incubated with labeled in vitro–translated Tat
protein. In addition, the deletion of the COOH-terminal
activation domain of IRF-1 strongly reduced the binding
to Tat (Fig. 5, top panel).
Yeast Two-Hybrid Systems. To verify the Tat and IRF-1
interaction in vivo, the yeast two-hybrid system (53) was
used. Although IRF-1 showed in this assay intrinsic tran-
scriptional activation of the reporter gene (Table I), lacZ
expression was significantly increased by Tat confirming an
interaction between the two proteins. Deletions of the
COOH-terminal region of IRF-1 abolished the effect con-
firming the involvement of this IRF-1 region in binding to
Tat. In addition, due to the presence of the transcription
activation domain of IRF-1 in the COOH-terminal, dele-
Figure 4. IRF-1 and IRF-2 bind t he HIV-
ISRE. (A) Nuclear cell extracts (20  g) from Jurkat
cells uninfected or infected with HIV-1 IIIB strain
(5,000 cpm/ml) were prepared at different time
points after infection and incubated with an oligo-
nucleotide corresponding to the four tandem IRF-
binding sites (C13). Supershift assays were per-
formed in the presence of specific anti–IRF-1 and
anti–IRF-2 antibodies as indicated. Binding com-
plexes were resolved by PAGE and visualized by
autoradiography. (B) DNA pull-down assays. Bio-
tinylated oligodeoxynucleotides containing the
wild-type or a mutated version of the HIV-ISRE
(Materials and Methods), coupled to Streptavidin
MagneSphere were incubated with nuclear extracts
from Jurkat cells or primary CD4  T cells infected
with the HIV-1 IIIB strain (5,000 cpm/ml). The
bound proteins were eluted from the beads by boil-
ing in sample buffer and analyzed by WB with anti-
bodies against IRF-1. INPUT indicates the level of
endogenous IRF-1 in the uninfected and infected
nuclear cell extracts (20  g) at the indicated time
points determined by WB analysis.
Figure 5. GST-pull down assays. The indicated IRFs (IRF-1, IRF-2,
IRF-3, IRF-4, IRF-7, IRF-8, a COOH-terminal deleted mutant of
IRF-1 [  IRF-1]), and Tat, were translated in vitro in the presence of
35[S] methionine as indicated in Materials and Methods and incubated
with recombinant GST–Tat or GST-IRF-1 fusion proteins immobilized
on glutathione-sepharose. Input corresponds to 10% of the 35[S]-labeled
proteins used in the binding experiments. The complexes were resolved
by PAGE and detected by autoradiography. Binding of 35[S]-labeled pro-
teins to beads containing only GST protein is also shown. Quantitation of
incorporated radioactivity was performed by Instant Imager.1365 Sgarbanti et al.
tions of this region also resulted in decreased intrinsic tran-
scriptional activity as compared with the full length IRF-1.
Altogether these results indicate that IRF-1 and Tat physi-
cally associate and that the COOH-terminal activation do-
main of IRF-1 is involved in this interaction.
Binding of Endogenous IRF-1 by Immobilized GST–Tat.
To verify the binding of intracellular IRF-1 with Tat, Jur-
kat cells were treated or were not treated with IFN-  for
4 h in order to optimally stimulate IRF-1 expression. Nu-
clear extracts were then incubated with equal amounts of
the GST alone or the GST–Tat fusion protein. After ex-
tensive washing, associated proteins were resolved by SDS/
PAGE and detected by WB. As shown in Fig. 6 A, a poly-
clonal antibody specific for IRF-1 detected a major band
corresponding to IRF-1 in IFN- –induced cells (lane 4)
but not in control cells (lane 7), where IRF-1 was only
barely detectable. Beads containing a GST–Tat fusion pro-
tein were able to selectively bind IRF-1 (lane 6). Con-
versely, incubation of cell extracts with GST-control beads
retained no proteins in controls (lane 8) as well as in cell
extracts from IFN- –treated cells (lane 5). As control of
specificity, the in vitro–translated IRF-1 (lane 1) was incu-
bated with GST–Tat (lane 3).
Coimmunoprecipitation. To determine the in vivo inter-
actions between IRF-1 and Tat, coimmunoprecipitation
experiments were performed in 293 HEK cells cotrans-
fected with the expressing vectors for IRF-1 and Tat. After
cotransfection, anti–IRF-1 antibodies were used for immu-
noprecipitation followed by immunoblot with anti-Tat an-
tibodies. As shown in Fig. 6 B, the Tat protein was readily
detected in the anti–IRF-1 immunocomplexes obtained
from cells cotransfected with both RcCMV/IRF-1 or Rc-
CMV/Tat, whereas Tat was not detected in cells trans-
fected with RcCMV/IRF-1 or RcCMV/Tat alone (Fig. 6
B). Vice versa, when immunoprecipitation was performed
with anti-Tat antibodies followed by immunoblot with
anti–IRF-1 antibodies, the IRF-1 protein coimmunopre-
cipitated with Tat in cells extracts of doubly transfected
cells (data not shown). Altogether these results indicate that
IRF-1 and Tat associate intracellularly.
IRF-8 but not IRF-2 Represses the IRF-1-Tat–mediated
Transactivation of the HIV-1 LTR. IRF-2 is the transcrip-
tional repressor of IRF-1 and acts by competing for IRF-1
binding to target sequences on cellular genes. Since both
IRF-1 and IRF-2 can bind the ISRE present in the HIV-1
LTR (reference 8, and this paper), experiments were per-
formed to verify whether IRF-2 could repress the IRF-1
effect on the HIV-1 LTR. Jurkat cells were transiently
cotransfected with the HIV-1 LTR-CAT vector and with
the expression vectors for Tat, IRF-1, and IRF-2, respec-
tively. As shown in Fig. 7 A, IRF-2 had no effect on LTR-
directed transcription and was unable to inhibit IRF-1–
mediated transactivation of the HIV-1 LTR, both in the
presence or in the absence of Tat.
IRF-8 is another repressor of IRF-1 activity on cellular
target genes. IRF-8 does not bind to DNA but acts
mainly through complessing IRF-1 and/or IRF-2. As
shown in Fig. 7 B, the expression of IRF-8 inhibited by
20% the Tat-mediated transactivation of the HIV-LTR in
transient transfection assays. Therefore, to better evaluate
Table I. In Vivo Interaction between IRF-1 and Tat by the
Two-Hybrid System
VP16 VP16-Tat
LexA 0.54   0.1 0.53   0.03
LexA–IRF-1 581   27 819   117
LexA–IRF-1 (1-291) 453   80 539   105
LexA–IRF-1 (1-234) 131   65 121   10
Yeast strain DBY1 was transformed with the yeast expression vectors
Yeplac181G (Leu2) containing LexA or LexA-IRFs sequences, pRS314
(Trp1) containing VP16TAD or VP16TAD-Tat, and the LacZ reporter
vector pSH18 (Ura3). Transformants were selected and analyzed as
described in Materials and Methods.  -galactosidase activity is expressed
as mean  -galactosidase units   SD.
Figure 6. IRF-1 and Tat associate intracellularly. (A) In vitro–translated
IRF-1 (lanes 1–3) and nuclear cell extracts from Jurkat cells treated with
IFN-  (lanes 4–6) or control medium (lanes 7–9) were incubated with
purified GST–Tat fusion protein or GST alone. Bound proteins were
then analyzed by WB using anti–IRF-1 polyclonal antibody as described
in Materials and Methods. 10% of the extract used for binding assays is
shown in lane 7 (untreated cells) and lane 4 (IFN- -treated cells). The
slowly migrating IRF-1p* band observed in IFN- –treated cell extracts is
due to the phosphorylation induced by IFN-  (reference 64). Extra bands
in lanes 7–9 are not specific. (B) 293 HEK cells were transfected with the
expression plasmids encoding IRF-1 or Tat, alone or in combination.
Whole cell extracts (300  g) were immunoprecipitated with anti–IRF-1
antibodies ( IRF-1). Immunoprecipitated complexes were separated by
10% SDS-PAGE and subsequently probed with anti-Tat antibodies
( Tat) as indicated. Whole cell extracts (10  g) were separated on 10% or
15% SDS-PAGE and probed with anti-Tat or anti–IRF-1 antibodies.1366 IRFs and HIV-1 Replication
the IRF-8 inhibitory effect, Jurkat cells were stably trans-
duced with IRF-8 and then transfected with the HIV-
LTR CAT construct and the Tat-expression vector. After
selection, transgene expression was assessed by RNase
protection assay (Fig. 7 C). Bulk populations of trans-
fected cells were chosen to avoid clonal variability. As
shown in Fig. 7 D, the constitutive expression of IRF-8
reduced by  50% both the IRF-1 and the Tat-directed
HIV-1-LTR transcription.
Inhibition of HIV-1 Replication in IRF-8–expressing Cells.
To evaluate the inhibitory effect of IRF-8 on virus replica-
tion, Jurkat cells stably expressing IRF-8 or control cells
containing the vector alone were infected with 1,000 and
5,000 cpm/ml, corresponding to 0.001/0.005 TCDI50 per
cell of the HIV-1 IIIB strain virus. The accumulation of
HIV-1 RNA species was then evaluated by semiquantita-
tive RT-PCR (Fig. 8 A) at 24 and 48 h after infection. In
control cells (lanes 1, 3, and 5), all HIV transcripts (un-
spliced, singly- or multi-spliced) were clearly detected after
2 d of infection. In contrast, in IRF-8–expressing cells
(lanes 2, 4, and 6), a significant decrease of both spliced and
unspliced viral RNA was observed at both infection doses,
the doubly-spliced tat/rev being the more reduced. This
correlated with an abolished or a reduced virus replication
(Fig. 8 B). Specifically, at a low multiplicity of infection,
p24 antigen production was, only barely detectable at 48 h
after infection and undetectable at later time points, as
compared with control cells. Similarly, a reduction of  3
logs was progressively observed, in cells infected with 5,000
cpm/ml of virus. This indicates that IRF-8 represses HIV-1
productive infection.
IRF-8 Blocks Activation of HIV-1 LTR Transcription by In-
terfering with IRF-1–Tat Binding. Since no direct activity
of IRF-8 on LTR transcription nor a direct binding of
IRF-8 to Tat was detected (Figs. 5 and 7), to investigate
the molecular mechanism(s) responsible for IRF-8–medi-
ated inhibition of HIV, GST-pull down assays were per-
formed with in vitro–translated IRF-1 and IRF-8, and the
labeled proteins were tested for binding to a GST–Tat fu-
sion protein. As shown in Fig. 9, the binding of IRF-1 to
the GST–Tat beads was clearly impaired in the presence of
IRF-8, since the IRF-1 input retained on the GST–Tat
beads was reduced by  50% (compare lanes 2 and 3). On
the other hand, the presence of IRF-2 did not affect the
IRF-1 binding to immobilized Tat (compare lanes 3 and
4). These results indicate that the inhibitory effect exerted
by IRF-8 is, at least in part, mediated by the competition
of IRF-8 and Tat for the binding to IRF-1.
To further support this conclusion, Jurkat cells express-
ing IRF-8 were stably transduced also with an IRF-1–
expressing vector. After selection, transgene expression was
assessed by RNase protection analysis with RcCMV/IRF-8
cells (control) and with RcCMV/IRF-8/IRF-1 doubly
transfected cells (Fig. 10 A). A polyclonal population of
cells overexpressing both IRF-8 and IRF-1 was then in-
fected with 1,000 and 5,000 cpm/ml and the production of
the HIV p24 antigen evaluated. The dramatic reduction of
p24 accumulation in IRF-8 constitutively expressing cells
Figure 7. IRF-8 but not IRF-2 inhibits the IRF-1-mediated and Tat-
mediated HIV-1 LTR activity. (A and B) Transient cotransfections were
performed with the HIV-LTR CAT reporter construct (1  g) and IRF-1,
IRF-2, IRF-8 (1  g), or Tat (5 ng) expression vectors, respectively, as in-
dicated. CAT activity was quantified 48 h after transfection. (C) RNase
protection assay with a IRF-8–specific antisense riboprobe on total RNA
extracted from Jurkat cells transfected with an empty vector or an IRF-8–
expressing vector. IRF-8 indicates the transcript of the transduced gene
and IRF-8e the endogenous recognized transcript. 18S RNA was used as
a control of RNA loading and tRNA as a control of specificity. (D) Jurkat
cells constitutively expressing IRF-8 or the empty vector were transiently
transfected with the Tat-expressing vector (20 ng) or IRF-1–expressing
vector (1  g) along with the HIV-LTR reporter construct and CAT ac-
tivity quantified as described in B. The results quantified by an Instant
Imager are reported as mean levels   SE from three separate experiments.1367 Sgarbanti et al.
was reversed by at least 50–70% in the cells overexpressing
also IRF-1 (Fig. 10 B). Thus, IRF-1 overcomes the inhibi-
tory effect of IRF-8 on HIV-1 replication.
Discussion
HIV-1 transcription and replication is controlled by both
viral and cellular factors, which act at the transcriptional,
posttranscriptional, and/or translational levels. Both basal-
and tissue-specific transcription factors that are essential for
HIV-1 have been identified. In the present report we ex-
amined the role of the cellular IRFs in HIV-1 transcription
and replication and their interactions with the viral transac-
tivator Tat.
We identified IRF-1 as an essential factor for efficient
HIV-1 gene expression especially in the early phase of viral
replication and before expression of Tat. Several lines of
evidence support this conclusion: (i) IRF-1 activates LTR-
driven transcription in the absence of the viral transactiva-
tor Tat; (ii) IRF-1 is induced at very early time after virus
infection and before expression of Tat; (iii) IRF-1 expres-
sion during infection correlates with a specific binding to
the ISRE of the HIV-1 LTR; (iv) in the presence of low
doses of Tat, IRF-1 increases Tat-mediated HIV-1 transac-
tivation by a direct physical interaction with Tat through
its transactivation domain; (v) IRF-8, a dominant negative
regulator of IRF-1 activity, blocks HIV-1 transcription
both in vitro and in vivo, and inhibition is released by
overexpression of IRF-1.
The role of IRFs in the regulation of IFN and ISGs (54–
56), as well as of genes expressed during inflammation, im-
mune responses, hematopoiesis, cell proliferation, and dif-
ferentiation has been clearly defined (10, 11). The recent
identification of an ISRE on the HIV-1 LTR downstream
the transcription start site together with the demonstration
that sequences comprising the ISRE are essential for effi-
cient HIV-1 transcription and virus replication (8, 9), al-
lowed us to speculate that IRFs exert a role in HIV-1 tran-
scription. Indeed we demonstrated that IRF-1, but not
other IRFs, activates the HIV-1 promoter. IRF-1 may,
thus, effectively activate transcription of Tat and, in turn,
amplify HIV-1 transcription and virus replication. This can
be particularly relevant at the initial phases of HIV-1 repli-
cation when viral transactivators are not yet synthesized or
are present at subthreshold concentrations.
This has biological significance since IRF-1 is stimulated
early after virus infection and before expression of Tat in
both cell lines and primary CD4  T lymphocytes. The ki-
netic of IRF-1 induction closely resembles that described
in cells infected by the vesicular stomatitis virus or Newcas-
tle disease virus, where IRF-1 expression precedes IFN
Figure 8. Inhibition of HIV-1 replication in IRF-8–expressing Jurkat
cells. Jurkat cells stably transfected with the IRF-8 (lanes 2, 4, and 6) or
the RcCMV (control vector) (lanes 1, 3, and 5) were infected with the
HIV-1 IIIB strain at an infectious dose corresponding to 1,000 or 5,000
cpm/ml of RT activity. (A) Cells were collected after 24 and 48 h and to-
tal RNA analyzed by RT-PCR, as described in Materials and Methods.
(B) HIV-p24 antigen production. After 48, 72 and 144 h, p24 antigen
accumulation was determined in the cell supernatants as indicated in Ma-
terials and Methods.
Figure 9. IRF-8 inhibits the binding of IRF-1 to immobilized Tat.
Recombinant GST–Tat fusion protein was immobilized on glutathione
agarose beads and incubated with the indicated 35[S]-labeled IRFs as de-
scribed in Materials and Methods. Input corresponds to 10% of the 35[S]-
labeled proteins used in the binding experiments; in lanes 1, 5, and 6 are
shown the in vitro labeled IRF-8, IRF-2, and IRF-1, respectively. In
lane 2, 35[S]-labeled IRF-1 and IRF-8 were incubated together for 15
min at room temperature before the addition of GST–Tat fusion protein
beads. Lane 3 shows the binding of 35[S]-labeled IRF-1 alone to GST–
Tat beads. In lane 4, 35[S]-labeled IRF-1 and IRF-2 were preincubated
together for 15 min at room temperature before the addition of GST–Tat
fusion protein beads.1368 IRFs and HIV-1 Replication
type I production (7). Therefore, HIV-1 seems to have
evolved a strategy to turn the IRF-1 activity to its own ad-
vantage, before massive IFNs production.
Our results point also to a potential role of IRF-1 dur-
ing viral reactivation from latency. A stable reservoir of
HIV-1 are latently infected resting CD4  T cells (57). La-
tent infection occurs in resting cells, whereas reactivation
occurs only in activated T cells and is dependent on host
transcription factors (58–60). IRF-1 that is present at dis-
crete levels in activated but not in resting T cells (51) can
thus contribute to viral reactivation even in the absence of
Tat. Consistent with this, proinflammatory cytokines such
as IFN- , IL-6, and TNF-  which lead to cell activation
and drive HIV-1 replication (61) strongly activate IRF-1
(62, 63). In addition, the induced IRF-1 can still bind to
Tat (Fig. 6) leading to further induction of LTR activation
and virus replication. Therefore, we propose that IRF-1
exerts a key role in initiating and amplifying transcription
from the HIV-1 LTR, increasing production of Tat,
which, in turn, thereby amplifies LTR-directed gene ex-
pression. Consistent with this, IRF-1 binds to Tat and co-
operates with suboptimal doses of Tat to activate transcrip-
tion (Figs. 1 and 5). Of note both Tat and IRF-1 have
been shown to functionally interact with general transcrip-
tion factors such as TFIIB (12, 33) and coactivators or
adaptors, such as the histone acethyltransferases p300/CBP
and pCAF (13, 35–37). These interactions occur through
different domains of the proteins thus, IRF-1 might mod-
ulate the HIV-1 LTR promoter activity also by acting as a
bridge between Tat and component(s) of the basal tran-
scriptional machinery and/or may participate to the Tat-
holoenzyme complex according to the model proposed by
Cujec et al. (23). It remains to clarify at what extent IRF-1
is critical for HIV-1 replication in T cells. To this purpose
a strategy leading to inhibition of IRF-1 expression both
basal- and virus-induced, but not interfering with cell via-
bility, should be investigated.
In addition to activate HIV gene expression and replica-
tion the IRF system can also repress it specifically, since we
showed that IRF-8 is able to impair the binding of IRF-1
to Tat in vitro and to drastically reduce HIV-1 replication
in vivo and that this block is released by the simultaneous
overexpression of IRF-1. It is, thus, conceivable that, since
IRF-8 does not contain an activation/repression domain,
excess of IRF-8 complessing IRF-1 may inhibit the IRF-
1–induced LTR transcription and the binding of IRF-1 to
Tat further impairing HIV-1 replication ultimately leading
to a block of viral replication. These data, therefore, suggest
that an increase in IRF-8 expression can be involved in the
establishment of latency, whereas activation of IRF-1 ex-
pression functions as a positive regulator of HIV-1 tran-
scription and replication. Thus the differential expression of
these IRFs in activated versus non activated cells and in dif-
ferent cell types may determine productive infection and/
or virus reactivation at different tissue sites.
We thank J. Hiscott, B. Levi, T. Taniguchi, and I. Julkunen for
providing reagents; E. Stellacci and A.L. Remoli for the pull-down
experiments; P. Monini for helpful discussion; R. Orsatti, E. Bene-
detti, D. Fulgenzi, and E. Giacomini for technical assistance; R. Gi-
lardi for art work; and S. Tocchio and R. Tomasetto for editorial
assistance.
This work was supported by Italian grants from the AIDS
Project to B. Ensoli and A. Battistini and from AIRC and AN-
LAIDS to B. Ensoli.
Submitted: 2 May 2001
Revised: 13 March 2002
Accepted: 9 April 2002
References
1. Cullen, B.R. 1991. Regulation of HIV-1 gene expression.
FASEB J. 5:2361–2368.
2. Van Lint, C., J. Ghysdael, P. Paras, Jr., A. Burnyand, and E.
Figure 10. IRF-1 overexpression releases the inhibition of HIV-1 rep-
lication by IRF-8. Bulk populations of Jurkat cells stably transfected with
IRF-8 were engineered to constitutively express IRF-1. (A) RNase pro-
tection with a IRF-1–specific antisense riboprobe on total RNA ex-
tracted from IRF-8–expressing cells, transfected with an empty vector
(RcIRF-8/Rc), or with an IRF-1–expressing vector (RcIRF-8/IRF-1).
18S RNA was used as a control of RNA loading and tRNA as a control
of specificity. (B) Cells were infected with the HIV-1 IIIB strain as in Fig.
8 and after 48, 72, and 144 h, HIV p24 antigen accumulation was deter-
mined in the cell supernatants as indicated in Materials and Methods.1369 Sgarbanti et al.
Verdin. 1994. A transcriptional regulatory element is associ-
ated with a nuclease-hypersensitive site in the pol gene of hu-
man immunodeficiency virus type. J. Virol. 68:2632–2648.
3. Jones, K.A., and B.M. Peterlin. 1994. Control of RNA initi-
ation and elongation at the HIV-1 promoter. Annu. Rev. Bio-
chem. 63:717–743.
4. Gaynor, R. 1992. Cellular transcription factors involved in
the regulation of HIV-1 gene expression. AIDS. 6:347–363.
5. el Kharroubi, A., and E. Verdin. 1994. Protein-DNA interac-
tions within DNase I-hypersensitive sites located downstream
of the HIV-1 promoter. J. Biol. Chem. 269:19916–19924.
6. Gross, D.S., and W.T. Garrard. 1988. Nuclease hypersensi-
tive sites in chromatin. Annu. Rev. Biochem. 57:159–197.
7. Harada, H., T. Fujita, M. Miyamoto, Y. Kimura, M.
Maruyama, A. Furia, T. Miyata, and T. Taniguchi. 1989.
Structurally similar but functionally distinct factors, IRF-1
and IRF-2, bind to the same regulatory elements of IFN and
IFN-inducible genes. Cell. 58:729–739.
8. Van Lint, C., C.A. Amella, S. Emiliani, M. John, T. Jie, and
E. Verdin. 1997. Transcription factor binding sites down-
stream of the human immunodeficiency virus type 1 tran-
scription start site are important for virus infectivity. J. Virol.
71:6113–6127.
9. Liang, C., X. Li, Y. Quan, M. Laughrea, L. Kleiman, J. His-
cott, and M.A. Wainberg. 1997. Sequence elements down-
stream of the human immunodeficiency virus type 1 long
terminal repeat are required for efficient viral gene transcrip-
tion. J. Mol. Biol. 272:167–177.
10. Nguyen, H., J. Hiscott, and P.M. Pitha. 1997. The growing
family of interferon regulatory factors. Cytokine Growth Factor
Rev. 8:293–312.
11. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka.
2001. IRF family of transcription factors as regulators of host
defence. Annu. Rev. Immunol. 19:623–655.
12. Wang, I.M., J.C. Blanco, M.J. Tsai, and K. Ozato. 1996. In-
terferon regulatory factors and TFIIB cooperatively regulate
interferon-responsive promoter activity in vivo and in vitro.
Mol. Cell. Biol. 16:6313–6324.
13. Merika, M., A.J. Williams, G. Chen, T. Collins, and D. Tha-
nos. 1998. Recruitment of CBP/p300 by the IFN   enhan-
ceosome is required for synergistic activation of transcription.
Mol. Cell. 1:277–287.
14. Hiscott, J., P. Pitha, P. Genin, H. Nguyen, C. Heylbroeck,
Y. Mamane, M. Algarte, and R. Lin. 1999. Triggering the
interferon response: the role of IRF-3 transcription factor. J.
Interferon Cytokine Res. 19:1–13.
15. Wu, Y., and J.W. Marsh. 2001. Selective transcription and
modulation of resting T cell activity by preintegrated HIV
DNA. Science. 293:1503–1506.
16. Jeang, K.T., and A. Gatignol. 1994. Comparison of regula-
tory features among primate lentiviruses. Curr. Top. Microbiol.
Immunol. 188:123–144.
17. Chang, H.-K., R.C. Gallo, and B. Ensoli. 1995. Regulation
of cellular gene expression and function by the human im-
munodeficiency virus type 1 Tat protein. J. Biomed. Sci.
2:189–202.
18. Cullen, B.R. 1992. Mechanism of action of regulatory pro-
teins encoded by complex retroviruses. Microbiol. Rev. 56:
375–394.
19. Peterlin, B.M., M. Adams, A. Alonso, A. Baur, S. Ghosh, X.
Lu, and Y. Luo. 1993. Tat trans-activator. In Human Retro-
viruses. B.R. Cullen, editor. IRL Press, Oxford, UK. pp. 74–96.
20. Bohan, C.A., F. Kashanchi, B. Ensoli, L. Buonaguro, K.A.
Boris-Lawrie, and J.N. Brady. 1992. Analysis of Tat transacti-
vation of human immunodeficiency virus transcription in
vitro. Gene Expr. 2:391–407.
21. Jones, K.A. 1997. Taking a new TAK on tat transactivation.
Genes Dev. 11:2593–2599.
22. Jeang, K.T., R. Chun, N.H. Lin, A. Gatignol, C.G. Glabe,
and H. Fan. 1993. In vitro and in vivo binding of human im-
munodeficiency virus type 1 Tat protein and Sp1 transcrip-
tion factor. J. Virol. 67:6224–6233.
23. Cujec, T.P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg,
and B.M. Peterlin. 1997. The human immunodeficiency vi-
rus transactivation Tat interacts with the RNA polymerase II
holoenzyme. Mol. Cell. Biol. 17:1817–1823.
24. Berkhout, B., A. Gatignol, A.B. Rabson, and K.-T. Jeang.
1990. TAR-independent activation of the HIV-1 LTR: evi-
dence that Tat requires specific regions of the promoter. Cell.
62:757–767.
25. Alcami, J., T. Lain de Lera, L. Folgueira, M.A. Pedraza, J.M.
Jacqué, F. Bachelerie, A.R. Noriega, R.T. Hay, D. Harrich,
R.B. Gaynor, et al. 1995. Absolute dependence on  B re-
sponsive elements for initiation and Tat-mediated amplifica-
tion of HIV transcription in blood CD4 T lymphocytes.
EMBO J. 14:1552–1560.
26. Harrich, D., J. Garcia, R. Mitsuyasu, and R. Gaynor. 1990.
TAR independent activation of the human immunodefi-
ciency virus in phorbol ester stimulated T lymphocytes.
EMBO J. 9:4417–4423.
27. Buonaguro, L., F.M. Buonaguro, G. Giraldo, and B. Ensoli.
1994. The human immunodeficiency virus type 1 Tat pro-
tein transactivates tumor necrosis factor   gene expression
through a TAR-like structure. J. Virol. 68:2677–2682.
28. Brother, M.B., H.K. Chang, J. Lisziewicz, D. Su, L.C.
Murty, and B. Ensoli. 1996. Block of Tat-mediated transacti-
vation of tumor necrosis factor   gene expression by poly-
meric-TAR decoys. Virology. 222:252–256.
29. Roebuck, K.A., M.F. Rabbi, and M.F. Kagnoff. 1997. HIV-1
Tat protein can transactivate a heterologous TATAA element
independent of viral promoter sequences and the trans-acti-
vation response element. AIDS. 11:139–146.
30. Kashanchi, F., G. Piras, M.F. Radonovich, J.F. Duvall, A.
Fattaey, C.M. Chiang, R.G. Roeder, and J.N. Brady. 1994.
Direct interaction of human TFIID with the HIV-1 transac-
tivator Tat. Nature. 367:295–299.
31. Chiang, C.M., and R.G. Roeder. 1995. Cloning of an in-
trinsic human TFIID subunit that interacts with multiple
transcriptional activators. Science. 267:531–536.
32. Yu, L., P.M. Loewenstein, Z. Zhang, and M. Green. 1995.
In vitro interaction of the human immunodeficiency virus
type 1 Tat transactivator and the general transcription factor
TFIIB with the cellular protein TAP. J. Virol. 69:3017–3023.
33. Veschambre, P., A. Roisin, and P. Jalinot. 1997. Biochemical
and functional interaction of the human immunodeficiency
virus type 1 Tat transactivator with the general transcription
factor TFIIB. J. Gen. Virol. 78:2235–2245.
34. Herrmann, C.H., and A.P. Rice. 1995. Lentivirus Tat pro-
teins specifically associate with a cellular protein kinase, TAK,
that hyperphosphorylates the carboxyl-terminal domain of
the large subunit of RNA polymerase II: candidate for a Tat
cofactor. J. Virol. 69:1612–1620.
35. Hottiger, M.O., and G.J. Nabel. 1998. Interaction of human
immunodeficiency virus type 1 Tat with the transcriptional
coactivators p300 and CREB binding protein. J. Virol. 72:
8252–8256.1370 IRFs and HIV-1 Replication
36. Marzio, G., M. Tyagi, M.I. Gutierrez, and M. Giacca. 1998.
HIV-1 Tat transactivator recruits p300 and CREB-binding
protein histone acetyltransferases to the viral promoter. Proc.
Natl. Acad. Sci. USA. 95:13519–13524.
37. Benkirane, M., R.F. Chun, H. Xiao, V.V. Ogryzko, B.H.
Howard, Y. Nakatani, and K.-T. Jeang. 1998. Activation of
integrated provirus requires histone acetyltransferase. p300
and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem.
273:24898–24905.
38. Ensoli, B., L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendel-
man, R.A. Morgan, P. Wingfeld, and R.C. Gallo. 1993. Re-
lease, uptake and effects of extracellular human immunodefi-
ciency virus type 1 Tat protein on cell growth and viral
transactivation. J. Virol. 67:277–287.
39. Lin, R., A. Mustafa, H. Nguyen, D. Gewert, and J. Hiscott.
1994. Mutational analysis of interferon (IFN) regulatory fac-
tors 1 and 2. Effects on the induction of IFN-  gene expres-
sion. J. Biol. Chem. 269:17542–17549.
40. Lin, R., C. Heylbroeck, P.M. Pitha, and J. Hiscott. 1998. Vi-
rus-dependent phosphorylation of the IRF-3 transcription
factor regulates nuclear translocation, transactivation poten-
tial, and proteasome-mediated degradation. Mol. Cell. Biol.
18:2986–2996.
41. Lin, R., Y. Mamane, and J. Hiscott. 2000. Multiple regula-
tory domains control IRF-7 activity in response to virus in-
fection. J. Biol. Chem. 275:34320–34327.
42. Coccia, E.M., N. Del Russo, E. Stellacci, R. Orsatti, E. Bene-
detti, G. Marziali, J. Hiscott, and A. Battistini. 1999. Activa-
tion and repression of the 2-5A synthetase and p21 gene pro-
moters by IRF-1 and IRF-2. Oncogene. 18:2129–2137.
43. Saura, M., C. Zaragoza, C. Bao, A. McMillan, and C.J. Lo-
wenstein. 1999. Interaction of interferon regulatory factor-1
and nuclear factor  B during activation of inducible nitric
oxide synthase transcription. J. Mol. Biol. 289:459–471.
44. Glisin, V., R. Crkvenjakov, and C. Byus. 1974. Ribonucleic
acid isolated by cesium chloride centrifugation. Biochemistry.
13:2633–2637.
45. Coccia, E.M., E. Stellacci, M. Valtieri, B. Masella, T. Feccia,
G. Marziali, J. Hiscott, U. Testa, C. Peschle, and A. Battis-
tini. 2001. Ectopic expression of interferon regulatory fac-
tor-1 potentiates granulocytic differentiation. Biochem. J. 360:
285–294.
46. Borsetti, A., C. Parolin, B. Ridolfi, L. Sernicola, A. Geraci,
B. Ensoli, and F. Titti. 2000. CD4-independent infection of
two CD4 /CCR5 /CXCR4  pre-T-cell lines by human
and simian immunodeficiency viruses. J. Virol. 74:6689–
6694.
47. Kwon, H., N. Pelletier, C. DeLuca, P. Genin, S. Cisterna,
R. Lin, M.A. Wainberg, and J. Hiscott. 1998. Inducible ex-
pression of I B  repressor mutants interferes with NF- B
activity and HIV-1 replication in Jurkat T cells. J. Biol. Chem.
273:7431–7440.
48. Moscufo, N., F. Sverdrup, D.E. Breiding, and E.J. Andro-
phy. 1999. Two distinct regions of the BPV1 E1 replication
protein interact with the activation domain of E2. Virus Res.
65:141–154.
49. Dalton, S., and R. Treisman. 1992. Characterization of SAP-1,
a protein recruited by serum response factor to the c-fos se-
rum response element. Cell. 68:597–612.
50. Golemis, E.A., I. Serebriiskii, R.L. Finley, Jr., H.G. Kolo-
min, J. Gyuris, and R. Brent. 1999. Current Protocols in
Molecular Biology. John Wiley and Sons, Inc., New York.
2001.1–2001.40.
51. Nelson, N., Y. Kanno, C. Hong, C. Contursi, T. Fujita, B.J.
Fowles, E. O’Connell, J. Hu-Li, W.E. Paul, D. Jankovic, et
al. 1996. Expression of IFN regulatory factor family proteins
in lymphocytes. Induction of Stat-1 and IFN consensus se-
quence binding protein expression by T cell activation. J. Im-
munol. 156:3711–3720.
52. Fujii, Y., T. Shimizu, M. Kusumoto, Y. Kyogoku, T. Tani-
guchi, and T. Hakoshima. 1999. Crystal structure of an IRF-
DNA complex reveals novel DNA recognition and coopera-
tive binding to a tandem repeat of core sequences. EMBO J.
18:5028–5041.
53. Fields, S., and O. Song. 1989. A novel genetic system to de-
tect protein-protein interactions. Nature. 340:245–246.
54. Maniatis, T., and H. Weintraub. 1992. Gene expression and
differentiation. Curr. Opin. Genet. Dev. 2:197–198.
55. Taniguchi, T., H. Harada, and M. Lamphier. 1995. Regula-
tion of the interferon system and cell growth by the IRF
transcription factors. J. Cancer Res. Clin. Oncol. 121:516–520.
56. Kimura, T., K. Nakayama, J. Penninger, M. Kitagawa, H.
Harada, T. Matsuyama, N. Tanaka, R. Kamijo, J. Vilcek,
T.W. Mak, and T. Taniguchi. 1994. Involvement of the
IRF-1 transcription factor in antiviral responses to interfer-
ons. Science. 264:1921–1924.
57. Siciliano, R.F. 1999. Latency and reservoirs for HIV-1.
AIDS. 13:49–58.
58. Nabel, G., and D. Baltimore. 1987. An inducible transcrip-
tion factor activates expression of human immunodeficiency
virus in T cells. Nature. 326:711–713.
59. Tong-Starksen, S.E., P.A. Luciw, and B.M. Peterlin. 1987.
Human immunodeficiency virus long terminal repeat re-
sponds to T-cell activation signals. Proc. Natl. Acad. Sci. USA.
84:6845–6849.
60. Greene, W.C. 1990. Regulation of HIV-1 gene expression.
Annu. Rev. Immunol. 8:453–475.
61. Fauci, A.S. 1996. Host factors and the pathogenesis of HIV-
induced disease. Nature. 384:529–534.
62. Fujita, T., L.F. Reis, N. Watanabe, Y. Kimura, T. Tanigu-
chi, and J. Vilcek. 1989. Induction of the transcription factor
IRF-1 and interferon-  mRNAs by cytokines and activators
of second-messenger pathways. Proc. Natl. Acad. Sci. USA.
86:9936–9940.
63. Abdollahi, A., K.A. Lord, B. Hoffman-Liebermann, and
D.A. Liebermann. 1991. Interferon regulatory factor 1 is a
myeloid differentiation primary response gene induced by in-
terleukin-6 and leukemia inhibitory factor: role in growth in-
hibition. Cell Growth Differ. 2:401–407.
64. Sharf, R., D. Meraro, A. Azriel, A.M. Thornton, K. Ozato,
E.F. Petricoin, A.C. Larner, F. Schaper, H. Hauser, and
B.-Z. Levi. 1997. Phosphorylation events modulate the abil-
ity of interferon consensus sequence binding protein to inter-
act with interferon regulatory factors and to bind DNA. J.
Biol. Chem. 272:9785–9792.